GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » La Jolla Pharmaceutical Co (NAS:LJPC) » Definitions » EV-to-Revenue

La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) EV-to-Revenue : 2.38 (As of Apr. 26, 2024)


View and export this data going back to 1994. Start your Free Trial

What is La Jolla Pharmaceutical Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, La Jolla Pharmaceutical Co's enterprise value is $110.59 Mil. La Jolla Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 was $46.49 Mil. Therefore, La Jolla Pharmaceutical Co's EV-to-Revenue for today is 2.38.

The historical rank and industry rank for La Jolla Pharmaceutical Co's EV-to-Revenue or its related term are showing as below:

LJPC' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.55   Med: 9.6   Max: 8701.26
Current: 2.38

During the past 13 years, the highest EV-to-Revenue of La Jolla Pharmaceutical Co was 8701.26. The lowest was -1.55. And the median was 9.60.

LJPC's EV-to-Revenue is not ranked
in the Biotechnology industry.
Industry Median: 7.68 vs LJPC: 2.38

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), La Jolla Pharmaceutical Co's stock price is $6.22. La Jolla Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $1.49. Therefore, La Jolla Pharmaceutical Co's PS Ratio for today is 4.18.


La Jolla Pharmaceutical Co EV-to-Revenue Historical Data

The historical data trend for La Jolla Pharmaceutical Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

La Jolla Pharmaceutical Co EV-to-Revenue Chart

La Jolla Pharmaceutical Co Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 8.12 2.26 2.75 1.11

La Jolla Pharmaceutical Co Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.12 0.94 1.11 1.33 0.75

Competitive Comparison of La Jolla Pharmaceutical Co's EV-to-Revenue

For the Biotechnology subindustry, La Jolla Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


La Jolla Pharmaceutical Co's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, La Jolla Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where La Jolla Pharmaceutical Co's EV-to-Revenue falls into.



La Jolla Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

La Jolla Pharmaceutical Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=110.585/46.492
=2.38

La Jolla Pharmaceutical Co's current Enterprise Value is $110.59 Mil.
La Jolla Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $46.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


La Jolla Pharmaceutical Co  (NAS:LJPC) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

La Jolla Pharmaceutical Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=6.22/1.488
=4.18

La Jolla Pharmaceutical Co's share price for today is $6.22.
La Jolla Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.49.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


La Jolla Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of La Jolla Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Business Description

Traded in Other Exchanges
N/A
Address
201 Jones Road, Suite 400, Waltham, MA, USA, 02451
La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.
Executives
Larry G. Edwards director, officer: Chief Executive Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
David A Ramsay director HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121
Craig A Johnson director C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Michael S Hearne officer: Chief Financial Officer 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Robert Rosen director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Kevin C Tang director, 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Laura L. Johnson director C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Darryl Wellinghoff officer: Chief Commercial Officer 4550 TOWNE CENTRE COURT SAN DIEGO CA 92121
Lakhmir S Chawla officer: Chief Medical Officer 1960 KIRBY ROAD, MCLEAN VA 22101
Jennifer Carver officer: Sr. Vice President, Operations 725 NEWPORT STREET, DENVER CO 80220
James Rolke officer: Chief Scientific Officer 10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
George F Tidmarsh director, officer: President, CEO & Secretary

La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Headlines

From GuruFocus

Innoviva to Acquire La Jolla Pharmaceutical Company

By Business Wire Business Wire 07-11-2022